Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis: The RITUXERA Trial

NCT06003283 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.

NCT NCT06003283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06003283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis: The RITUXERA Trial
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Phase 4
Overall status
Recruiting
Start date
January 9, 2024
Completion date
December 31, 2027
Enrollment
134 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis